Thursday, April 26, 2018
8:00 AM - 8:40 AM REGISTRATION
Welcome coffee and networking
8:40 AM - 8:50 AM CHAIRMAN'S OPENING ADDRESS
Anita Varma, Intellectual Property Partner, White & Case
Charles Larsen, Intellectual Property Partner, White & Case
 
8:50 AM - 9:20 AM GLOBAL PATENT ENFORCEABILITY
Global Patent Enforceability: Status and Outlook​

Moderator:
Arlene Chow, Partner, Hogan Lovells

Panellists:
James Harrington, Chief Intellectual Property Counsel and Senior Vice President, Shire Pharmaceuticals
Konstantinos Andrikopoulos, Senior Director, IP, Vertex Pharmaceuticals
Philip Strassburger, Senior Vice President, Intellectual Property Strategy & Litigation, Purdue Pharma 
Shahan Islam, Senior Corporate Counsel, IP Enforcement Group, Pfizer Inc

9:20 AM - 9:50 AM EUROPEAN FOCUS

The Role of Equivalents

  • Developments in the UK – the implications of Actavis v Eli Lilly
  • Elsewhere in Europe, are equivalents considered?
  • What does this mean for life sciences companies in terms of patent protection and freedom to operate?
Zoe Butler, Partner, Powell Gilbert
9:50 AM - 10:10 AM THE NEW CANADIAN PMNOC REGULATIONS
  • The Use of the NIA Defence in Canada
  • How Courts are Reconciling a Finding of Patent Infringement with a Generic’s  s.8 Damages Claim  
  • How the Federal Courts are Handling the Utility Issues following the SCC’s Decision in AstraZeneca
Gunars Gaikis, Partner. Smart & Biggar
10:10 AM - 10:40 AM IMMUNOTHERAPIES FOCUS

Panel Discussion

The IP Landscape of Cancer Immunotherapies

  • Strategic approaches to protect IP rights in cancer immunotherapy
  • Licensing and commercialization considerations in cancer immunotherapy
  • Patents vs. trade secrets: Decision calculus for protecting cell-based cancer therapies
  • Updates regarding Patents 4 Patients, the USPTO’s Cancer Immunotherapy Pilot Program

Moderator:
James Ewing, Partner, Foley & Lardner

Panellists: 
Shilpi Banerjee, Chief IP Counsel, Memorial Sloan Kettering Cancer Center
Jason Dinges, Investment Professsional and IP Counsel, Morningside Technology Advisory
Mary Till, Senior Legal Advisor, USPTO

10:40 AM - 11:00 AM ASIA MARKET INSIGHT

Recent Developments in Pharma Patent Case Law in Japan

Takanori Abe, Managing Partner, Abe & Partners

11:00 AM - 11:30 AM MORNING COFFEE AND NETWORKING  
11:30 AM - 11:45 AM BIOLOGICS FOCUS

How do we Ensure Effective Protection for Antibodies?

Duane C. Marks, Patent Counsel, Bio-Products, Eli Lilly and Company
11:45 AM - 12:15 PM BIOLOGICS PANEL DISCUSSION
CHAMPIONING CUTTING EDGE INNOVATION WITH ROBUST PATENT PROTECTION
Panel Discussion
Biologics and Biosimilars
  • Why do the differences between biosimilars and generics matter?
  • Do biologics necessitate date exclusivity protection?
  • How do we Ensure Effective Protection for Antibodies?
 
Moderator:
Kristina Bieker-Brady, Partner, McDermott Will & Emery
Panellists:
Paul Inman, Partner, Gowling WLG
Nathan Edwards, Director, IP, Vertex Pharmaceuticals
Michael Yamauchi, Senior Director & Patent Counsel, Alexion
Duane C. Marks, Patent Counsel, Bio-Products, Eli Lilly and Company
12:15 PM - 12:35 PM SECOND MEDICAL USE
Addressing Second Medical Use Infringement
 
Martina Tyreus Hufnal, Partner, Fish & Richardson
12:35 PM - 1:05 PM BAYH-DOYLE PANEL DISCUSSION

Panel Discussion

Does the US Government Have Rights to Your IP Under Bayh-Dole?

Moderator:
Rolando Medina, Partner, Choate, Hall & Stewart
Robert Sahr, Counsel, Choate, Hall & Stewart

1:05 PM - 1:55 PM LUNCH BREAK
Lunch and Networking in the Hamilton Room
1:55 PM - 2:00 PM ROUNDTABLE DISCUSSION GROUPS
Taking part in these discussions offers delegates and speakers the opportunity to focus on topics of specific interest, within a small group. 35 minutes is set aside for each rotation – and delegates may choose two discussion tables. The roundtable discussion groups give delegates even more opportunity to share knowledge and opinion, and ends with a moderator round-up of key findings, providing delegates with an insight into all eight topics.
 
SESSION 1 - PLEASE CHOOSE YOUR FIRST TABLE FROM THE FOLLOWING:
2:10 PM - 2:55 PM ROUNDTABLE - 1

Considerations When Drafting CRISPR Patent Applications

Catherine Coombes, Patent Director, HGF

2:10 PM - 2:55 PM ROUNDTABLE - 7

Experimental Data Requirements and Admissibility of Post-filing Experimental Data in China

Juhua Luo, Deputy Director of Chemical Department, CCPIT Patent and Trademark Law Office

2:10 PM - 2:55 PM ROUNDTABLE - 5

Life Sciences Patents Open Table: Solving in-house counsel challenges  

Sally Shorthose, Partner, Bird & Bird

2:10 PM - 2:55 PM ROUNDTABLE - 8

Compulsory Licensing and Protecting Patented Drugs in India

Sunita Sreedharan, Founder & CEO, SKS Law

2:10 PM - 2:55 PM ROUNDTABLE - 9

Impact of IPR and PGR proceedings on Biologics and Biosimilars

Jennifer Fox, Partner, Brinks Gilson & Lione

2:10 PM - 2:55 PM ROUNDTABLE - 6

Venue in Hatch-Waxman Cases after T.C. Heartland

Brendan O’Malley, Partner, Fitzpatrick, Cella, Harper & Scinto

2:10 PM - 2:55 PM ROUNDTABLE - 2

Strategies in Second Medical Use Cases

Lydia McNally, VP, Oncology and US Patent Site, Novartis

2:10 PM - 2:55 PM ROUNDTABLE - 3

Licensing and joint ownership of IP: Who has Control?

Brion Berman, Senior Licensing Associate, Office of Research and Commercialisation, University of Central Florida

2:10 PM - 2:55 PM ROUNDTABLE - 4

How do we Ensure Effective Protection of Antibodies?

Eldora Ellison, Director, Biotech/Chemical and Litigation Practice Groups, Sterne, Kessler, Goldstein & Fox
Bonnie Nannenga-Combs, Director, Sterne, Kessler, Goldstein & Fox

 
2:10 PM - 2:55 PM ROUNDTABLE - 10

Pitfalls in Claim Drafting From a Litigator’s Perspective 

Brian Slater, Partner, Kramer Levin

2:55 PM - 3:00 PM SESSION 2 - PLEASE CHOOSE YOUR SECOND TABLE FROM THE FOLLOWING:  
3:00 PM - 3:40 PM ROUNDTABLE - 9

Impact of IPR and PGR proceedings on Biologics and Biosimilars

Jennifer Fox, Partner, Brinks Gilson & Lione

3:00 PM - 3:40 PM ROUNDTABLE - 2

Strategies in Second Medical Use Cases

Lydia McNally, VP, Oncology and US Patent Site, Novartis

3:00 PM - 3:40 PM ROUNDTABLE - 10

Pitfalls in Claim Drafting From a Litigator’s Perspective 

Brian Slater, Partner, Kramer Levin

3:00 PM - 3:40 PM ROUNDTABLE - 1

Considerations When Drafting CRISPR Patent Applications

Catherine Coombes, Patent Director, HGF

3:00 PM - 3:40 PM ROUNDTABLE - 8

Compulsory Licensing and Protecting Patented Drugs in India

Sunita Sreedharan, Founder & CEO, SKS Law

3:00 PM - 3:40 PM ROUNDTABLE - 6

Venue in Hatch-Waxman Cases after T.C. Heartland

Brendan O’Malley, Partner, Fitzpatrick, Cella, Harper & Scinto

3:00 PM - 3:40 PM ROUNDTABLE - 3

Licensing and joint ownership of IP: Who has Control?

Brion Berman, Senior Licensing Associate, Office of Research and Commercialisation  University of Central Florida 

 
3:00 PM - 3:40 PM ROUNDTABLE - 4

How do we Ensure Effective Protection of Antibodies?

Eldora Ellison, Director, Biotech/Chemical and Litigation Practice Groups, Sterne, Kessler, Goldstein & Fox
Bonnie Nannenga-Combs, Director, Sterne, Kessler, Goldstein & Fox

3:00 PM - 3:40 PM ROUNDTABLE - 7

Experimental Data Requirements and Admissibility of Post-filing Experimental Data in China

Juhua Luo, Deputy Director of Chemical Department, CCPIT Patent and Trademark Law Office

3:00 PM - 3:40 PM ROUNDTABLE - 5

Life Sciences Patents Open Table: Solving in-house counsel challenges  

Sally Shorthose, Partner, Bird & Bird

3:40 PM - 4:00 PM ROUND UP
Discussion group round-up: Key findings and points of note
4:00 PM - 4:20 PM BREAK
Afternoon Tea and Networking in the Hamilton Room
4:20 PM - 4:40 PM TRADE SECRETS
Is it Advisable to use Trade Secrets Protection rather than Patenting?
 
Philip Strassburger, SVP, IP Strategy & Litigation, Purdue Pharma
4:40 PM - 4:55 PM IP PORTFOLIO MANAGEMENT CASE STUDY

Don’t Rock the Boat - Change is a frightening proposition.

Mitchell Atherton, Global Strategy Director, Ship Global IP

4:55 PM - 5:30 PM IN-HOUSE PANEL DISCUSSION
Panel Discussion

IP Portfolio Management and Licensing Strategies: In-house Counsel Day-to-Day Challenges in Securing and Protecting Patents 

Moderator:
Andrea Reid, Partner, Dechert

Panellists:
Scott Alban, Vice President, Global Intellectual Property, AstraZeneca
Natasha Jones, Commercialisation Manager, University of Kentucky
Jeffrey Kopacz, Senior Director, Senior Patent Counsel, Alnylam Pharmaceuticals
Laural Boone, Senior Director & Patent Counsel, Alexion Pharmaceuticals
Tom McLean, Intellectual Property Counsel, Nimbus Therapeutics

5:35 PM - 6:30 PM CHAIRMAN'S CLOSING REMARKS & DRINKS RECEPTION